Abstract
B cells are increasingly being recognized as a major contributor to both T- and B-cell mediated allograft rejection, and as a barrier to transplantation in allosensitized and autoimmune patients. B-cell functions of interest to solid organ and bone marrow transplantation include antibody production, antigen presentation, and provision of costimulatory signals for T-cell activation. Several therapeutic antibody preparations induce apoptosis or complement-mediated B-cell death, and hold promise for use as immunomodulating agents in solid organ transplantation. In this review, we discuss the anti-B-cell activity of polyclonal rabbit antithymocyte globulin (Thymoglobulin), the monoclonal antibodies, rituximab and alemtuzumab, and pooled intravenous human immunoglobulin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
